Glaukos (NYSE: GKOS) targets $1bn in sales. Can Epioxa offset iDose risk?

Glaukos Corporation (NYSE: GKOS), the California-based ophthalmic pharmaceutical and medical technology company, reported record third-quarter 2026 revenue of US$211 million, up 58%, and introduced a preliminary US$1 billion sales target for 2027 following unexpectedly strong demand for its eye disease treatments. The October 28 results prompted an approximately 18% after-hours share-price surge as investors responded to higher guidance and the company’s return to quarterly profitability. Glaukos Corporation increased its 2026 sales forecast to US$775 million to US$785 million, a US$90 million improvement at the midpoint, reflecting accelerating commercial adoption of its iDose TR glaucoma treatment and newly launched Epioxa therapy for keratoconus. However, the investment case now hinges on whether the Epioxa launch can sustain rapid growth while proposed Medicare coverage restrictions create uncertainty around future iDose TR utilisation.

Why did Glaukos shares surge after management unexpectedly raised its 2026 revenue forecast?

Glaukos Corporation’s quarterly results substantially exceeded market expectations. Revenue increased from US$133.5 million a year earlier to US$211 million, surpassing the approximately US$168 million expected by analysts. Adjusted diluted earnings reached US$0.47 per share, compared with expectations for a loss of approximately US$0.10 per share. The company also recorded US$2 million in statutory net income, reversing a US$16.2 million loss in the corresponding quarter of 2025.

The more significant development was the scale of the guidance revision. Management raised its full-year revenue outlook from US$680 million to US$700 million previously to US$775 million to US$785 million, representing a 13% increase at the midpoint. It simultaneously introduced preliminary guidance for US$1 billion in revenue during 2027, suggesting another approximately 28% increase over the revised 2026 midpoint. That prospective growth rate is considerably stronger than the trajectory previously reflected in published analyst estimates.

The announcement arrived after the regular New York Stock Exchange session had ended. Glaukos Corporation shares closed at US$181.43 on October 28, gaining just 0.14% during ordinary trading, before climbing to approximately US$214 by 7:59 p.m. Eastern Time. That represented an after-hours increase of approximately 18%, although extended-session quotations can change substantially before the next regular market opening.

The market response suggests that the size of the earnings surprise and the unexpectedly strong 2027 outlook materially altered near-term expectations. Nevertheless, the US$1 billion figure remains preliminary guidance rather than a contracted revenue commitment. Its credibility depends on the commercial performance of two products with different reimbursement arrangements and stages of adoption.

How much of Glaukos Corporation’s record quarterly growth came from iDose TR and Epioxa?

Two products accounted for most of Glaukos Corporation’s latest revenue momentum. iDose TR generated approximately US$76 million in third-quarter sales, while Epioxa contributed around US$53 million. Together, the products produced approximately US$129 million, equivalent to 61% of total quarterly revenue. Their increasing contribution also helped lift the company’s reported gross margin to approximately 85%, compared with 78% a year earlier.

iDose TR is an implantable drug-delivery treatment designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rather than relying exclusively on daily eye drops, the treatment provides sustained delivery of medication through a device implanted in the eye. Glaukos Corporation has been expanding physician training, treatment access and commercial adoption since the product’s initial regulatory approval. During the October earnings discussion, management indicated that 2026 iDose TR revenue could reach the low US$280 million range, more than double its 2025 performance.

Epioxa operates in a different therapeutic market. Approved by the United States Food and Drug Administration in October 2025, the therapy provides an epithelium-on corneal cross-linking treatment for keratoconus, a progressive condition that can distort the cornea and impair vision. The approach avoids removing the corneal epithelium during treatment, distinguishing it from the company’s earlier Photrexa-based procedure. Glaukos Corporation began its controlled commercial rollout during 2026 and completed the transition of its commercial and manufacturing efforts from Photrexa to Epioxa during the September quarter.

The resulting sales acceleration was substantial. Corneal Health revenue increased 154% to US$59 million, while United States Glaucoma revenue grew 47% to US$118.6 million. International glaucoma sales contributed another US$33.4 million, increasing 13% on a reported basis. The geographical and therapeutic diversification supports the overall growth profile, although the two principal United States products remain the most important drivers of near-term performance.

Epioxa’s early commercial success should also be interpreted in the context of the transition from Photrexa. The US$53 million Epioxa contribution does not represent entirely incremental revenue above a business with no existing corneal treatment sales. Part of the new product’s expansion replaces revenue previously generated by the older treatment platform. The economically relevant development is whether the new therapy can expand the number of eligible patients treated, increase commercial revenue and sustain attractive margins beyond the initial transition period.

Can Epioxa’s expanding treatment network support Glaukos Corporation’s $1 billion sales ambition?

Epioxa’s commercial rollout has progressed more rapidly than management initially expected. Glaukos Corporation reported more than 200 established treatment sites at the end of September, with contracts covering additional deployments that could expand the network beyond 300 locations. Its installed treatment systems were already positioned across locations serving approximately 90% of the United States population. These figures demonstrate expanding treatment infrastructure, although geographic access does not automatically mean that every eligible patient can obtain timely reimbursement.

Insurance access is becoming the next important commercial consideration. Management reported that reimbursement access pathways had been established for approximately 90% of commercially insured lives and more than 80% of Medicaid-covered lives. The permanent product-specific billing code J2789 became effective on July 1, 2026, helping standardise reimbursement administration for the therapy. However, individual insurers still determine coverage terms, prior authorisation requirements and payment processes.

The company has acknowledged that treatment authorisations can take different amounts of time across insurers. Even where an access pathway exists, patients and physicians may encounter administrative requirements before treatment can proceed. Glaukos Corporation is therefore investing in specialty pharmacy operations, patient support and reimbursement assistance alongside the physical expansion of its treatment network. Improving these processes could convert additional clinical interest into realised commercial sales.

Management has also identified opportunities to increase keratoconus diagnosis and treatment rates through physician education and screening. A new keratoconus screening device is expected to support commercial initiatives beginning in 2027, while disease-awareness activities aim to improve referral pathways. These developments could broaden the eligible patient population over time, but their eventual contribution cannot yet be calculated reliably.

The central commercial question is whether the initial Epioxa launch momentum can continue once the earliest adopting treatment centres have been established. A sustained increase in active treatment sites, patient procedures and insurance approvals would provide stronger evidence of recurring demand than the opening-quarter revenue contribution alone. Further improvements in reimbursement processing could also increase productivity at existing sites without requiring proportionate growth in the physical network.

Could proposed Medicare coverage restrictions weaken iDose TR revenue growth during 2027?

The most important unresolved regulatory issue concerns proposed Medicare Local Coverage Determinations for iDose TR. During the second quarter of 2026, five of the seven regional Medicare Administrative Contractors published proposed coverage criteria for the treatment. The public comment period ended in July, but the proposals had not become final coverage policies at the time of Glaukos Corporation’s October earnings announcement.

The distinction between proposed restrictions and final reimbursement decisions is essential. The relevant contractors may issue final policies, modify their proposals or abandon the process under applicable procedures. Management indicated that the contractors generally have a year from the May draft publication to act or withdraw their proposals. If final determinations are issued, a further 45-day period would apply before they become effective.

The commercial concern is that more restrictive eligibility criteria could limit the number of patients receiving reimbursed iDose TR treatment. Glaukos Corporation’s management believes existing clinical evidence supports broader access and has participated in the consultation process alongside physicians and other stakeholders. That assessment reflects the company’s position, while the actual coverage outcome remains subject to the decisions of the relevant Medicare contractors.

A recent clinical development provides additional context. On October 9, Glaukos Corporation reported positive topline results from a Phase 4 randomised trial evaluating iDose TR alongside cataract surgery. At three months, patients receiving the combined treatment experienced an average intraocular-pressure reduction of 11.1 mmHg, compared with 7.4 mmHg for cataract surgery alone. The results demonstrated a statistically significant incremental treatment effect, although they do not guarantee a particular Medicare coverage decision.

Management addressed the reimbursement uncertainty directly when introducing its US$1 billion preliminary 2027 revenue target. President and Chief Operating Officer Joe Gilliam explained that the outlook had been developed after considering multiple potential scenarios, including restrictive final coverage decisions broadly resembling the proposed policies. He indicated that management still identified pathways to the revenue target under those assumptions, but declined to provide a detailed product-by-product forecast.

This creates an important test of the investment thesis. The US$1 billion forecast is not necessarily dependent on unrestricted iDose TR reimbursement, but its achievement may require stronger contributions from Epioxa and other businesses if glaucoma treatment growth slows. Until the final coverage outcome and management’s more detailed 2027 guidance become available, the allocation of expected revenue between those businesses remains uncertain.

Are Glaukos Corporation’s expanding gross margins translating into sustainable profitability?

The latest financial results provide evidence of stronger product economics. Reported gross margin increased to approximately 85%, while non-GAAP gross margin reached almost 88%, compared with approximately 84% in the previous year’s third quarter. Management attributed much of the improvement to the increasing revenue contribution from iDose TR and Epioxa. Both products currently offer attractive gross-margin characteristics relative to the company’s wider historical mix.

However, expenses associated with commercialisation remain substantial. Selling, general and administrative expenses increased 58% to US$130.9 million, while research and development spending rose 26% to US$48.1 million. Consequently, statutory operating income reached only approximately US$0.8 million despite US$211 million in quarterly revenue. Non-GAAP operating income was significantly higher at US$27.3 million, reflecting the effect of adjustments excluded from that measure.

The difference between statutory and adjusted results matters when assessing profitability. Glaukos Corporation reported US$28.5 million in adjusted quarterly net income, but only US$2 million under generally accepted accounting principles. The reported quarter therefore demonstrates a substantial improvement in underlying operating performance without yet establishing consistently high statutory profitability. For the first nine months of 2026, the company remained loss-making, recording a US$36.1 million net loss despite 50% revenue growth.

Cash generation has nevertheless improved. Operating activities generated US$40.9 million during the first nine months, compared with US$21.6 million used in the corresponding period of 2025. The reported cash flow included significant non-cash adjustments, notably share-based compensation, while higher accounts receivable absorbed working capital as iDose TR and Epioxa sales expanded. The improvement is encouraging, but further evidence is needed to establish how consistently sales growth will translate into collected cash.

Glaukos Corporation ended September with approximately US$339.8 million in cash, short-term investments and restricted cash, and reported no financial debt. This provides flexibility to support commercial expansion and research programmes without the immediate borrowing pressures faced by some earlier-stage medical technology businesses. Nevertheless, future product development, manufacturing investment and potential licensing commitments will continue requiring capital.

Is Glaukos stock expensive after its earnings-driven surge towards new highs?

Glaukos Corporation shares had already advanced before the earnings announcement. The October 28 regular-session closing price of US$181.43 was approximately 2.6% above its October 21 close and 14.4% higher than the September 28 closing price of US$158.56. Its regular-session 52-week range extended from US$73.16 to US$191.62, showing that the stock had recovered substantially from its previous low even before the after-hours rally.

At US$181.43 and approximately 59.17 million shares outstanding, Glaukos Corporation had an equity market capitalisation of roughly US$10.7 billion. The subsequent after-hours quotation near US$214 implied a valuation of approximately US$12.7 billion using the same share count. These figures represent separate market snapshots rather than an official new regular-session closing valuation.

The higher valuation places considerable weight on future commercial growth. At US$214, the implied equity value is approximately 16.3 times the midpoint of 2026 revenue guidance and 12.7 times preliminary 2027 revenue guidance. These are price-to-sales comparisons using management projections rather than earnings-based valuation multiples or indications of intrinsic value.

Such valuations can be supported by businesses delivering sustained high growth, strong gross margins and improving cash generation. However, they also increase sensitivity to changes in treatment adoption, reimbursement or product economics. The company’s transition to quarterly profitability is positive, but its first-nine-month statutory loss demonstrates that the mature earnings profile associated with the valuation has not yet been established.

Published analyst assessments before the latest results were generally constructive, reflecting expectations for the new product launches. However, estimates prepared before the US$1 billion forecast may no longer provide an appropriate comparison with the latest financial outlook. Investors will need to assess updated forecasts rather than treating older targets as a current consensus.

The more optimistic interpretation is that Epioxa and iDose TR are creating a high-margin ophthalmic treatment business capable of sustaining substantial growth. A more cautious interpretation recognises that the share price increasingly assumes successful commercial execution while the Medicare coverage issue remains unresolved. The next financial results and regulatory developments will help establish which assumptions are better supported.

What milestones must Glaukos achieve before its $1 billion revenue target becomes credible?

The first milestone is delivery against the upgraded 2026 forecast. Glaukos Corporation generated US$547.2 million in revenue during the first nine months, meaning fourth-quarter sales must reach approximately US$227.8 million to US$237.8 million to achieve the new annual range. That represents sequential growth of approximately 8% to 13% over the September quarter. The calculation provides a near-term and measurable test of management’s expectations.

The second milestone is the outcome of the proposed Medicare coverage determinations for iDose TR. A decision maintaining broad treatment access could support continued utilisation growth, while restrictive final policies could alter the trajectory of the glaucoma business. Management’s more detailed 2027 product forecasts should help clarify the contribution expected from iDose TR under the applicable reimbursement arrangements.

The third milestone is the scale and productivity of Epioxa’s treatment network. Growth beyond 300 contracted treatment sites, improving payer authorisation processes and higher procedure volumes would provide evidence of a commercially sustainable launch. The company must also demonstrate that its growing presence in corneal health produces incremental earnings rather than being offset entirely by additional marketing and support expenses.

Glaukos Corporation has moved considerably closer to a diversified, profitable ophthalmic business, supported by record sales, expanding gross margins and stronger operating cash generation. The latest results demonstrate genuine commercial momentum rather than relying solely on future clinical-development promises. Yet the preliminary US$1 billion revenue target still depends on product adoption, reimbursement conditions and the company’s ability to sustain high margins while increasing commercial investment.

The strongest confirmation of the investment case would be a combination of continued Epioxa growth, manageable iDose TR reimbursement outcomes and durable statutory profitability. Conversely, restrictive coverage decisions, slower patient access or rising commercial costs could reduce the financial returns expected from the revenue expansion. Following the after-hours share-price surge, the crucial question is no longer whether Glaukos Corporation can grow quickly, but whether its two flagship therapies can support the earnings profile implied by a significantly higher valuation.

Key takeaways: What should Glaukos investors watch after the third-quarter earnings surprise?

• Glaukos Corporation reported record third-quarter revenue of US$211 million, up 58%, and returned to a small statutory quarterly profit.
• Management raised 2026 sales guidance by US$90 million at the midpoint to US$775 million to US$785 million and introduced a preliminary US$1 billion revenue target for 2027.
• iDose TR generated approximately US$76 million in quarterly sales, while Epioxa contributed approximately US$53 million.
• The Epioxa launch is expanding rapidly, but sustained growth depends on treatment-site productivity, insurance access and patient adoption.
• Proposed Medicare coverage restrictions for iDose TR remain unresolved, although management says its preliminary 2027 outlook incorporates potential adverse scenarios.
• Glaukos Corporation reported approximately US$339.8 million in combined cash, investments and restricted cash with no debt, supporting continued commercial and pipeline investment.
• Stronger evidence for the investment case would include achieving fourth-quarter guidance, clarity on Medicare coverage, continued Epioxa growth and sustained profitability.